Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Feb 05, 2023 1:18pm
177 Views
Post# 35267722

RE:Insider Holdings

RE:Insider HoldingsFrom this table you begin to get a picture of what the insider's average share cost excluding warrants and options.
It would be interesting to calculate the average share price for the major shareholders.
With Mainpointe and Yofoto no calculation needed:
 Mainpoint holding 3,986,687 shares at $.675
 Yofoto holding 5,357,900 shares at $.95

With the other major shareholders, Andrew Schutte is by far the largest shareholder at 18,624,006 including warrants and options and his latest buy in.  I would assume with his last two buys his averge is now down below $.20.  Maybe closer to $.15.

With the other 10 larger shareholders their average share price looks to be above $.20.

With that in mind  a buyout price will be an interesting debate among these major shareholders. 
<< Previous
Bullboard Posts
Next >>